Servier signs $1.55B upfront deal for Edgewise

Servier will pick up the muscular dystrophy business from Edgewise Therapeutics, giving the French pharma company access to an experimental neuromuscular medicine that could have pivotal data by year Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure…

Source: Endpoints News